ArticleFrontiers in pharmacology2025
Plasticity of ventral tegmental area disturbance during abstinence after repeated amphetamine exposure: restoration by selective activation of group II metabotropic glutamate receptors.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of the Ventral Tegmental Area in Reward and Addiction: A Comprehensive Review.Neurosciences (Riyadh, Saudi Arabia) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: The psychostimulant actions of amphetamine (AMPH) have been correlated with its ability to orchestrate ventral tegmental area (VTA) dopamine (DA) neuron activity states and, thus, DA release in output regions: in rats, a single exposure is sufficient to reduce the fraction of spontaneously active DA neurons, i.e., DA neuron population activity, whereas AMPH abstinence after repeated exposure leads to an increase. Here, this switch in DA neuron activity was resolved in detail in mice, and its sensitivity towards activation of group II metabotropic glutamate receptor (mGluR2 and mGluR3) was investigated. Experimental procedure: All experiments were conducted on C57BL/6J male mice. After repeated AMPH administration (2 mg/kg), the amine was withdrawn for up to 15 days and VTA DA neuron activity was assessed. The involvement VTA afferent regions with respect to AMPH actions was analyzed either by local instillation of drugs or through inactivation by tetrodotoxin. Selective agonists or allosteric modulators of mGluR2 and mGluR3 were used to explore whether group II mGluR might interfere with VTA disturbances caused by the amine. Results: After repeated AMPH exposure, VTA DA neuron activity remained reduced for 4 days and then rose to a hyperdopaminergic state within 15 days. The initial hypodopaminergia was coordinated by an amygdala (AMG) - nucleus accumbens (NAc) -VTA pathway, whereas the hyperactivity relied on ventral hippocampus (vHPC). Hypodopaminergic VTA activity was recovered towards physiological levels by activation of mGluR2, but not mGluR3, and this remission was contingent on glutamatergic transmission within NAc and propagation via the ventral pallidum. Results of a light-dark transition task confirmed anxiolytic efficaciousness of mGluR2 activation. The hyperdopaminergic VTA activity, in contrast, was normalized by selective activation of mGluR3, but not mGluR2, within vHPC. AMPH re-exposure after abstinence turned VTA activity down, but this suppression involved alternative circuits and could no longer be rescued by mGluR activation. Conclusion: Thus, abstinence from repeated AMPH intake drives VTA activity from hypo-into hyperdopaminergic states, and both can be readjusted towards physiological levels via different members of group II mGluRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.